Jesper Lind - Orexo AB Advisor

All Insiders . USA . 
Stock . Orexo AB . Stakeholders . Insider . Jesper Lind
ORXOF Stock  USD 1.08  0.00  0.00%   

Executive

Mr. Jesper Lind was Chief Operating Officer at Orexo AB since November 2013. He has senior global pharmaceutical manufacturing and supply chain experience from AstraZeneca, Pharmacia Biosensor and AlfaLaval. He holds MS degree in Chemical Engineering, Royal Institute of Technology Stockholm, Sweden and Sydney University, Sydney, Australia. since 2013.
Age 63
Tenure 11 years
Phone46 1 87 80 88 00
Webhttps://www.orexo.com

Orexo AB Management Efficiency

The company has return on total asset (ROA) of (0.0965) % which means that it has lost $0.0965 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6535) %, meaning that it generated substantial loss on money invested by shareholders. Orexo AB's management efficiency ratios could be used to measure how well Orexo AB manages its routine affairs as well as how well it operates its assets and liabilities.
Orexo AB has accumulated 492.3 M in total debt with debt to equity ratio (D/E) of 1.76, which is about average as compared to similar companies. Orexo AB has a current ratio of 2.01, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Orexo AB until it has trouble settling it off, either with new capital or with free cash flow. So, Orexo AB's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Orexo AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Orexo to invest in growth at high rates of return. When we think about Orexo AB's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

James MarkenANI Pharmaceuticals
61
Christopher MDCollegium Pharmaceutical
N/A
Tomoko YamagishiDresslerEvolus Inc
N/A
Samantha WiddicombeBiofrontera
N/A
Francisco MangualcbdMD Inc
45
Krista DavisANI Pharmaceuticals
50
Shannon CharlescbdMD Inc
N/A
Zeb BookercbdMD Inc
N/A
MD FAAFPCollegium Pharmaceutical
63
Bart DunnCollegium Pharmaceutical
N/A
David JohnsoncbdMD Inc
54
Chad GassertANI Pharmaceuticals
48
Omri BatzirINC Research Holdings
N/A
Nareg SagherianEvolus Inc
N/A
Daniel JDBiofrontera
N/A
Alycia TorresBiofrontera
N/A
BA MAAkanda Corp
74
Jon MBABiofrontera
N/A
Bradley WhitfordcbdMD Inc
43
Jessica NovakEvolus Inc
N/A
Ori GutwergANI Pharmaceuticals
49
Orexo AB , a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Orexo AB was incorporated in 1994 and is headquartered in Uppsala, Sweden. Orexo Ab is traded on OTC Exchange in the United States. Orexo AB [ORXOF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Return On Equity-0.65
Return On Asset-0.0965

Orexo AB Leadership Team

Elected by the shareholders, the Orexo AB's board of directors comprises two types of representatives: Orexo AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orexo. The board's role is to monitor Orexo AB's management team and ensure that shareholders' interests are well served. Orexo AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orexo AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
Fredrik Jarrsten, Ex CFO
MD MBA, Chief Officer
Cecilia Coupland, VP Operations
Nikolaj Sorensen, Pres CEO
Lena Wange, Investor Relations & Communications Manager
Jesper Lind, Advisor
Dennis Urbaniak, Ex Therapeutics
Robert DeLuca, President of Orexo US Inc.
Robert Ronn, VP RD

Orexo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Orexo AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.65
Return On Asset-0.0965
Profit Margin(0.28) %
Current Valuation76.98 M
Shares Outstanding34.35 M
Shares Owned By Insiders17.29 %
Shares Owned By Institutions42.78 %
Price To Earning58.66 X
Price To Book2.02 X
Price To Sales0.99 X

Currently Active Assets on Macroaxis

FFord Motor
GOOGAlphabet Inc Class C
CRMSalesforce
VVisa Class A
FFord Motor

Other Information on Investing in Orexo OTC Stock

Orexo AB financial ratios help investors to determine whether Orexo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Orexo with respect to the benefits of owning Orexo AB security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY